高龄老年混合型高脂血症122例的治疗

目的:观察联合应用阿托伐他汀和非诺贝特治疗75岁以上混合型高脂血症的临床疗效及安全性。方法:混合型高血脂症患者122例,随机分为3组,即阿托伐他汀组(10 mg/d,n=40)、每日联合治疗组(阿托伐他汀10 mg/d+非诺贝特200 mg/d,n=40)、隔日联合治疗组(阿托伐他汀10 mg+非诺贝特200 mg隔日交替服用,n=42),治疗12周。观察治疗前、后主要血脂水平的变化率及不良反应。结果:联合用药组血脂参数变化显著,降低甘油三酯和升高高密度脂蛋白胆固醇的能力明显优于单药组(P<0.05);隔日联合治疗组不良反应发生率(7.1%)低于每日联合治疗组(17.5%)(P<0.05)。结论:隔日联合应用阿托伐他汀和非诺贝特治疗75岁以上混合型高脂血症较单药更有效,具有良好的安全性和耐受性。

Treatment of combined hyperlipidemia in 122 elderly patients

Objective： To investigate the efficacy and safety of atorvastatin combining with fenofibrate on combined hyperlipidemia in patients aged over 70 years old.Methods： A total of 122 patients with combined hyperlipidemia were randomly divided into atorvastatin group（atorvastatin 10 mg/d,n=40） consecutive combining treatment group（atorvastatin 10 mg/d plus fenofibrate 20 mg/d,n=40） and alternative treatment group（alternate use of atorvastatin 10 mg/d and fenofibrate 20 mg/d,n=42）.All 3 groups were treated for consecutive 3 weeks.Changes in the lipid level before and after the treatment,adverse effects were observed and compared.Results： In the combining treatment groups TG was significantly lowered and HDL-C increased compared with that in the atorvastatin group（P0.05）,incidence of side effects in the alternative treatment group was 7.1%,significant lower than that of the consecutive combining treatment group（17.5%）（P0.05）.Conclusions： With great safety and tolerance,alternative combining use of atorvastatin and fenofibrate is effective on combined hyperlipidemia patients aged over 75 years old.